Faeth Therapeutics (FTH) vs ProKidney (PROK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Faeth Therapeutics (FTH) has outperformed ProKidney (PROK) over the past year, gaining 121.4% versus a loss of 47.0%. Over five years, FTH leads with a -83.7% price change compared with -84.1% for PROK. Faeth Therapeutics is the larger company by market cap ($657.8 million vs $652.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FTH | PROK |
|---|---|---|
| Share price | $25.46 | $1.64 |
| Market cap | $657.77M | $652.66M |
| 1-day change | +2.15% | +4.14% |
| YTD return | +133.55% | -29.91% |
| 1-year return | +121.39% | -46.96% |
| 5-year return | -83.67% | -84.09% |
| EPS (TTM) | $-60.86 | $-0.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $42.14 | $3.48 |
| 52-week low | $7.45 | $1.30 |
| Distance from 52-week high | -39.60% | -53.02% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +122.63% | +282.26% |
| Average volume | 351.88K | 1.30M |
| Shares outstanding | 25.84M | 208.93M |
| Employees | 29 | 231 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FTH has outperformed PROK by 168.4 percentage points over the past year.
About Faeth Therapeutics
FTH stock →Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About ProKidney
PROK stock →ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 231 employees
FTH vs PROK FAQ
Which is bigger, Faeth Therapeutics or ProKidney?
Faeth Therapeutics (FTH) is larger, with a market capitalization of $657.77M compared with $652.66M for ProKidney (PROK).
Which stock has performed better over the past year, FTH or PROK?
FTH returned +121.39% over the past 12 months, compared with -46.96% for PROK (price return, excluding dividends). Past performance does not predict future results.
Are Faeth Therapeutics and ProKidney in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Faeth Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for ProKidney.